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“All animals  are equal, but some animals  are more equal than others” 
(George Orwell,  Animal Farm) 
 
Within the discourse of failed states, is the perennial debate about definitions of what 
makes a weak or failed state. The capacity of the state to protect its citizens from forces 
both within and outside its borders is one criterion relevant here.  Another criterion is the 
economic and social vulnerability of the people.  The significance of these two criteria of 
weak states in the age of globalization is because global corporations can take advantage 
of weak policies and institutions within that state in order to exploit the poverty and to be 
examined here the case of diseases of the people to use them as ‘guinea pigs’ in clinical 
drug trials, in many cases for drugs destined for the western market, for western illnesses. 
 
Indeed the pharmaceutical industry and its operations in developing countries have come 
to light in the wake of the success and publicity of the film The Constant Gardener 
(2005), based on John le Carre’s novel (2001) of the same name, and following from this, 
the release of Sonia Shah’s  non-fiction version of the same issues in the Body Hunter: 
Testing New Drugs on the World’s Poorest Patients (2006).  It will be argued here that 
this (dysfunctional) marriage between global corporations and weak states, especially 
across Africa, creates a form of ‘pharmaceutical colonialism’, that is enabled by the 
processes of globalization that impact upon the many vulnerable nations that have once 
endured colonization and now must survive a ‘new-colonialism’.  
 
This process, enhanced by globalization, can be clearly seen in the case which inspired 
John Le Carre’s fiction novel The Constant Gardener, the case of the clinical drug trials 
for Trovan (trovafloxacin), tested on children in Kano state, Nigeria in 1996.  This 
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exemplifies opportunities created by globalization for the benefit of pharmaceutical 
companies to profit from the African poverty.  That is, the pharmaceutical company 
Pfizer exploited a poverty induced medical crisis in Nigeria to extract data and profits, in 
a medical experiment that left a number of children dead or seriously ill. This is typically 
a one-way colonial extraction.  In 1996 there was an outbreak of meningitis in Kano state 
Nigeria, that affected thousands of children and Pfizer took advantage of this opportunity 
to test a new oral antibiotic called Trovan (Trovafloxacin).  The problem was, according 
to SOMO, that “Pfizer arrived several weeks after Médecins Sans Frontières” creating 
some confusion about their role as doctors and researchers. 
The drug was tested on children without parents’ informed consent, patients were 
unaware of the experiment, and the trial was not approved in advance by an 
ethical review committee. Out of 190 children that were enrolled in the trial, five 
receiving trovafloxacin and six receiving the existing treatment ceftriaxone [the 
injectable Rocephin] died. Others suffered brain damage and paralysis1. 
 
As Chippaux has noted, the justifications for the study protocols were weak, because they 
“overlooked the fact that the cost of the product and the limited chances of its 
commercialization without state subsidy ma[d]e its use in Africa highly unlikely”2.  
According to Shah, there were also warnings from within Pfizer, about the effectiveness 
of an oral drug on these particular children who were already sick, not only with 
meningitis but other illnesses, because the pre-existing injectable drug Rocephin worked 
more rapidly3.  Despite the results indicating that study drug Trovan was no better than 
the preexisting drug Rocephin,  the problem was that the researchers did not respect the 
rights of the participants, and as such, South African bioethicist Solomon Benetar has 
                                                 
1
 Somo, “Briefing paper on ethics in clinical trials, #1 Examples of Unethical Trials”, February 2008, 
http://www.somo.nl/html/paginas/pdf/Examples_of_unethical_trials_dec_2006_NL.pdf, (accessed May 
14th 2008).  Also see Jean-Phillipe Chippaux, “Pharmaceutical Colonialism in Africa” Le Monde 
Diplomatique, August 2005, translated by Donald Hounam, http://mondediplo.com/2005/08/11pharma   
(accessed 25 March 2008). 
2
 Chippaux, 2005 
3
 Sonia Shah, The Body Hunters: Testing New Drugs on the World’s Poorest Patients, (New Press, New 
York: London, 2006), pp.144-145 
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argued that this lack of respect is ‘colonial’4, because despite the questionable ethical 
conduct of this trial in Nigeria, and an unresolved class action put by 30 Nigerian families 
against Pfizer, the US Food and Drug Administration accepted the data from this trial5. 
 
From this example, we can ask if the big pharmaceutical companies and their contract 
research organizations (CROs), are exploiting the citizens of weak and/or developing 
states due to a failure or lack of ethical policies and rules designed to protect against 
unethical clinical drug trials? If big pharmaceutical companies can exploit the citizens of 
weak states, is this because globalization is a hindrance to state strength and of benefit 
only to global corporations? How can weak African states survive globalization, if 
globalization means ‘pharmaceutical colonialism’?   Indeed is ‘pharmaceutical 
colonialism’ an indicator of weak or failed states in Africa?  
 
Or do African states support the intervention and investments by pharmaceutical 
companies trialing new drugs in their health systems?  Does it make the state weak for 
approving clinical drug trials that would not be approved of in the western world, because 
they provided access to something (some drugs), which was better than nothing (no 
drugs)?  Is this ‘better than nothing’ approach to health development enabling the 
Millenium Development Goals of Global Health for All?6 Or does it signify a patronizing 
and colonizing outcome for weak and developing states in the age of globalization? 
 
The concept ‘pharmaceutical colonialism’ surfaces clearly in the literature on these 
questions and themes (often no more than a simple headline used to capture attention, and 
more often it is an accusation flung at big pharmaceutical companies for their alleged 
unethical practices in developing countries).  They are also criticized for creating an 
economic dependence on the west via the creation of a need for life saving drugs against 
illnesses of poverty, rather than more local remedies or strategies to alleviate poverty.   It 
was an article written by Jean-Phillipe Chippaux entitled “Pharmaceutical Colonialism in 
                                                 
4
 Solomon Benetar quoted by Shah, 2006, p.153.  Also see Jeremy Laurance, “The True Story of how 
multinational drug companies took liberties with African lives”, in The Independent/UK, September 26th, 
2005. 
5
 Shah, 2006, p.153. 
6
 see David Bloom “Governing Global Health”, in Finance and Development, December 2007.   
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Africa” published in Le Monde Diplomatique7 that appears to consolidate the evidence 
against pharmaceutical companies in their actions within Africa and other developing 
countries.  While Chippaux has not been the first author to use this term8, he does appear 
to be the first to coin the phrase in relation to clinical drug trials in Africa. Within the 
article he refers to the actions of pharmaceutical companies as ‘strategic imperialism’.  
Either of these terms indicates global power imbalances between developing countries’ 
peoples and global corporations that seek the former out for exploitation of one kind or 
another.  Chippaux’s argument is straight forward: 
the developing world is now a place where pharmaceutical companies ignore ethical 
considerations and the health of patients. Without the informed consent of their 
subjects who receive only the most basic information and usually inadequate 
therapeutic supervision, they conduct clinical trials with limited benefits to specific 
patients or the local population as a whole.9  
 
Chippaux’s ‘strategic imperialism’ implies that it is no longer necessary to colonise an 
entire country, as foreign forces (global pharmaceutical companies) only need to target 
the specific resource (in this case, poor, sick, treatment naïve populations) in order to 
extract the profits (data for new drug approvals).  Cumbersome colonial administrations 
have been replaced by the sophisticated and dynamic processes of globalization, which 
enables corporations (rather than countries) to operate within a nation-state (however 
                                                 
7
 Chippaux, 2005. Nonetheless, it could also be the result of Le Monde Diplomatique’s  editors coining this 
term, as it is only used in the title to his article. 
8
 Contributing to the discourse on this concept included references claiming that the Pill, or oral 
contraceptives used “to control the population of ethnic others, smacks of pharmaceutical colonialism”. See 
Sharra Vostral, “Reproduction, Regulation and Body Politics”, in Journal of Women’s History, Summer 
2003, Vol.15, Issue 2, p.197. Also, an earlier reference from Milton Silverman et al., describes “Drug 
Colonialism” as “the wanton manner by which the huge multinational pharmaceutical industry openly 
extracts an exorbitant profit by knowlingly trading on the health needs and even the lives of Third World 
nationals”. See Zachary Gussow’s “Review of ‘Prescriptions for death: The Drugging of the Third World’ 
(1982)”, in Medical Anthropology Quarterly, Vol 14, No. 3, May 1983, pp.24-25. Further evidence on the 
discourse of ‘pharmaceutical colonialism’ includes references to the search for new drugs and new 
biological resources by the pharmaceutical industry as a form of “neo-colonialism”.  That is, it is simply a 
“continuation of the colonial tradition of appropriating indigenous knowledge and resources”, by extracting 
knowledge and genetic material from the developing world, in order to benefit the west. See John Merson 
“Bio-Prospecting or Bio-Piracy: Intellectual Property Rights and Bio-Diversity in a colonial and 
postcolonial context”, in OSIRIS, 2nd Series, Vol. 15, Nature and Empire: Science and the Colonial 
Enterprise, 2000, pp.282-296. 
9
 Chippaux, 2005. Also see David Rothman, and Sheila Rothman, Trust is Not Enough: Bringing Human 
Rights to Medicine, (New York Review of Books, New York, 2006). 
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weak or strong), with or without official invitation or permission, and certainly with little 
ethical scrutiny10. 
 
Since 1990 the number of drug trials that have been conducted in developing countries 
has risen dramatically11.  There are a number of factors that have led Clinical Research 
Organisations (CROs), on behalf of pharmaceutical companies to conduct more trials in 
developing countries. They are the fact that now “80% of deaths from chronic non-
communicable diseases now occur in developing countries”12;  western illnesses have 
appeared in developing countries like cardiovascular problems (ie there are 20 million 
Africans suffering from hypertension) and diabetes (ie 90% of the world’s diabetes 
occurs in India and China); and AIDS -  being “the first modern infectious disease to 
strike the developed and developing world simultaneously and to give both a large stake 
in finding a cure”13.  Furthermore, these locations are cheaper to operate in, and there are 
less regulations; also in places like India and China they do have some kind of health 
infrastructure making them very attractive destinations.  Importantly, these larger 
populations are not as exposed to other treatments – they are ‘treatment naïve’ – making 
them ideal participants for various drug trials.  As Shah has pointed out these factors 
create great opportunities for drug trials to be conducted in those areas14, in particular 
because CROs can test more drugs relevant to the western markets15. 
                                                 
10
 Ethical considerations and regulations in relation to medical experiments and in particular 
pharmaceutical testing around the world, have been slow to develop and often only “in reaction to scandals 
and accidents” ( See Jean-Phillipe Chippaux, 2005). For example, the Nuremberg code was only adopted 
after the horrific experiments conducted by Nazis during the Holocaust ( See David Rothman and Sheila 
Rothman, 2006).  In 1964 the Helsinki Declaration was adopted as the next international regulatory model. 
And the 1981 Manila Declaration was aimed at clinical trials in developing countries. The problem with 
any of the recommendations made to ensure participants in trials are informed and give consent, is that they 
are “only recommendations and no sanctions [a]re proposed” (See  Chippaux, 2005). 
11
 Jean-Phillipe Chippaux, 2005: David Boath cited in Patrick McGee “Clinical Trials on the Move” Drug 
Discovery & Development - June 12, 2006 http://www.dddmag.com/clinical-trials-on-the-move.aspx : 
accessed May 9th 2008: Patrick McGee, 2006: See Peter Lurie and Sidney Wolfe, “Unethical Trials of 
Interventions to Reduce Perinatal Transmission of the Human Immunodeficiency Virus in Developing 
Countries”,  New England Journal of Medicine, Vol. 337, September 18, 1997, pp.853-856 
12
 Sonia Shah, “Outsourcing risks: testing new drugs on the world’s poor”, in Le Monde Diplomatique, 
June, 2007, accessed from www.global-sisterhood-network.org/content/view/1800/59/ March 25th 2008. 
13
 Rothman and Rothman 
14
 Sonia Shah, June 2007. Particularly popular are placebo trials that can quickly demonstrate that those 
given the active drug have fewer adverse events than those who do not (in the placebo arm), and this latter 
group need to have these events (eg. heart attacks) to prove that the drugs works.  Shah also points out that 
up to and over 40% of volunteers in trials in the west drop out or refuse to participate.  This demonstrates 
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The Quintiles website for example, boasts of their ability to access patients from ‘non-
traditional regions’ - 
For faster trials, start farther from home: More and more customers are discovering 
the advantages of conducting trials in the diverse nontraditional regions of the 
world, where patient populations, well-trained investigators and high-quality 
communications systems are readily available16. 
 
As a type of  ‘strategic imperialism’ in Africa it may not be as dominant as the scramble 
for Africa, because despite African countries being amongst the poorest and most disease 
burdened developing nations of the world, in 2001 only 1% of clinical trials were 
conducted in Africa17, and it is the other developing regions that are deemed more 
suitable, for example, in India which has a “1 billion body bounty”18.  Nonetheless, 
despite there being lesser opportunities in Africa, there are many notable exceptions and 
examples where these poorest and weakest countries have offered valuable ‘data’ to drug 
development companies and indeed future profits for the ‘imperial’ pharmaceutical 
corporations. For example, in 2003 CROs started flocking to South Africa where “cashed 
starved medical facilities welcomed them with open arms”19. 
 
Chippaux argues that Africa will be targeted by ‘unscrupulous' drug companies seeking 
quick and cheap locations with fewer regulations to test their drugs20.   The view is that 
African populations have less access to drugs, and while any existing health structures are 
weak at best, they still create ideal “epidemiological conditions” for clinical trials21.   
 
                                                                                                                                                 
that in developing countries where the retention rates are much higher, they cannot be fully aware of their 
volunteer status, or indeed they are not voluntarily consenting in the first place. 
15
 David Rothman and Sheila Rothman, 2006, p.69. 
16
 Quintiles website:  http://www.quintiles.com/SpotlightPages/PatientAccess.htm (accessed March 25th 
2008). 
17
 Chippaux, 2005.   
18
 Shah, 2006, p.112. Also see Marcia Angell, The Truth About the Drug Companies: How they deceive us 
and what to do about it, (Random House, New York, 2004). 
19
 Shah, 2006, p.104 
20
 Chippaux, 2005. 
21
 See Quintiles website, www.quintiles.com/Locations/Africa/SouthAfrica/ (accessed March 25th 2008): 
and Shah, 2006. 
 7 
The major problem or ethical consideration is not so much the number of trials but the 
relevance of the drugs being trialed on African populations22.  Are they drugs aimed for 
use in the African or western markets? For example, between 1972 and 1997 there were 
1,450 new medicines marketed globally, but “only 13 were for tropical diseases”23.  Most 
African governments do not have any ability to control which drugs get tested in their 
countries, since it is the pharmaceutical industry that ‘finances and organises’ these trials.  
As Joel Lexchin has pointed to the obvious, “the primary obligation of pharmaceutical 
corporations is to their shareholders, not to the people of the developing world”24.  It is 
simply about profit extraction – ‘strategic imperialism’!  According to Chippaux “by the 
end of the 1990s the pharmaceutical industry’s global turnover ($480bn) was greater than 
the GDP of all of the countries of Sub-Saharan Africa ($380bn)”25. 
  
Nundy and Gulhati have argued that this new focus on outsourcing clinical trials to these 
developing countries is a ‘new colonialism’, and it seems to be an indicator of a ‘weak 
state’ in particular, in relation to its health systems apparatus26.  As Shah argues, often 
even just the availability of clinical trials in developing countries is perceived as offering 
better health care than local health systems can provide27.  For example, in a Quintiles 
Fact Sheet on South Africa it claims that, 
Clinical trials in South Africa can be a blessing to patients as well as a boon to 
sponsors. First, they provide access to sophisticated care for a large portion of the 
                                                 
22
 While the 1990s and 2000s have seen critics lambaste the unethical conduct of pharmaceutical 
companies testing drugs in developing countries, the literature and the critics of the pharmaceutical industry 
in the 1980s tended to focus on the issue of the pharmaceutical corporation’s responsibility in providing 
relevant drugs to the developing world, and not to allow them to become the dumping ground for drugs not 
legal or not prescribed in the west. See  Mike Muller, The Health of Nations: A North-South Investigation, 
(Faber and Faber, London, 1982);  Dianna Melrose, Bitter Pills: Medicines and the Third World Poor, 
(Oxfam, Oxford, 1982);Surendra Patel (ed) Pharmaceuticals and Health in the Third World, (Pergamon 
Press, Oxford, 1983; and also ee Shah, 2006, p.103.  
23
 see P.Trouillet et al., “Is Orphan Drug Status Beneficial to Tropical Disease Control?”, in Tropical 
Medicine and International Health”, Oxford, Vol. 4, 1999, pp. 412-420, cited in Chippaux 2005.   
24
 Joel Lexchin, “Ethics, Drugs and the Developing World: What we should expect of the pharmaceutical 
industry?” Seminar presented to the Ethics Centre of South Australia, Tuesday May  6th, 2008, Adelaide. 
25
 Chippaux, 2005.  
26
 The drugs being tested are usually either not relevant to the future market setting within those countries, 
or if they are relevant they are marketed too expensive so become unaffordable to the majority of the 
population. This lack of relevancy is unethical according to these authors, because it is of no benefit to 
those societies.  See Samiram Nundy and Chandra Gulhati, “A New Colonialism? – Conducting Clinical 
Trials in India”, The New England Journal of Medicine, Vol. 352, Iss. 16, (April 21, 2005),  pp.1634.  
27
 Shah, June 2007. 
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population that generally receives only basic medical services and many who have 
not received previous treatment.28 
 
If clinical trials are seen as beneficial to ‘medicine deprived’ populations, and often “the 
only way they can get treatment”29, this suggests that a global pharmaceutical company 
can provide (strong) services to a (weak) state’s people. Is this considered a type of 
‘welcomed’ colonization? Does the global replace the local in terms of the state’s 
responsibilities for its own citizens?  However, the fact that the reason for a drug trial is 
to test its effectiveness which is unproven, hence the need for the trial, determines that it 
cannot be claimed that patients will be better off if they participate in a trial30, and as such 
that said service cannot replace the role of the (ideal) state.  Yet, the CRO will still 
benefit from the data produced, and thus it becomes undeniably  a new type of colonial 
exploitation.   
 
If we accept the argument that CROs and pharmaceutical companies are attempting a 
form of colonization in Africa, whether it is welcomed by them or not, what are the 
possible problems associated with that?   Firstly,   Megan Vaughan offers historical 
evidence for the perceived ‘pharmaceutical colonialism’ in Africa and explains one 
problem as the resistance to AIDS prevention techniques, such as using condoms31.  She 
argues that  these theories of ‘colonialism’ emanate from African fears, naivety and 
misconceptions surrounding vaccinations and other medicines from the west that are 
promoted for use on African populations.  Relevant here is the issue that with the 
colonization of Africa came a world view about modern bioscience and medicine which 
was at odds with and clashed with African culture and ‘primitive’ explanations for 
disease and subsequent cures.  There is no space to entertain the notion of a ‘good’ 
strategic colonization (or imperialism).  Thus, claims of a ‘pharmaceutical colonialism’ 
can cause an anti-western / anti-colonial reaction that is detrimental to the benefits that 
can be offered by western biomedicine within the gambit of any foreign intervention – 
                                                 
28
 Quintiles Fact Sheet: Patient Access: South Africa, www.quintiles.com  
29
 Shah, 2006, p.36. 
30
 Shah, June 2007. 
31
 Megan Vaughan, Curing Their Ills: Colonial Power and African Illness, (Polity Press, Cambridge, 
1991). 
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such as life saving drugs - the ‘good’ aspects of  this perceived ‘colonisation’. If exposed 
to media and public scrutiny as in the Trovan case above, an unintended result of these 
unethically conducted clinical trials in developing countries can be that western medicine 
is undermined. For example, in the late 1990s the polio vaccine was rejected in Nigeria, 
and HIV/AIDS drugs were ‘condemned’ by the South African government.  
 
This has led to a persuasive (but only to some) account of ‘pharmaceutical colonialism’, 
which has come from the title of a book written by Dr. Mathias Rath in South Africa – 
End AIDS! Break the Chains of Pharmaceutical Colonialism.  Denounced by medical 
experts,  this book argues that anti-retroviral drugs attack and destroy the body’s immune 
system and it accuses the pharmaceutical industry of using poor countries as a market 
place for their “toxic and often deadly drugs”32.    The authors argue that while there is 
political freedom in South Africa, “it is still been kept hostage by global economic 
interests, namely pharmaceutical colonialism”33.  This book reeks of conspiracy theories 
and lays claim to the debate on the benefits of natural health in combating AIDS, rather 
than the expensive drugs promoted by the global pharmaceutical industry.  Indeed the 
text of this book and the evidence cited really do not warrant any academic respect, but 
does need to be examined in its political context in how it influenced government policy 
to refuse proven drug therapies for AIDS treatment.  The former President of South 
Africa, Thabo Mbeki and his Minister for Health, Peggy Nkonyeni, conferred that HIV 
does not cause AIDS, anti-retrovirals are toxic, and are no cure for AIDS.   Thus, instead 
of approving the use of proven AIDS drugs, such as Nevaripine34, they wanted to 
promote indigenous and affordable remedies such as micronutrients, garlic, potatoes, 
lemon and olive oil - eating fresh vegetables to boost your immune system.  Not 
coincidentally, the book argues that AIDS is merely a “giant business opportunity” for 
                                                 
32
 cited in Celia Dugger, “Rift over AIDS Treatment Lingers in South Africa”, New York Times, March 9th, 
2008, p.A8 
33
 Dr. Rath Health Foundation, End Aids: Break the Chains of Pharmaceutical Colonialism, South African 
National Civic Organsiation (SANCO), 2006, www.dr-rath-foundation.org.za (accessed March 2008). 
34
 See Shah, 2006, p.104 
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foreign pharmaceutical companies, who want AIDS to spread so they can market their 
drugs, and force African governments to pay for them35.   
 
The basic premise of the Rath Foundation book is flawed. It argues that pharmaceutical 
colonialism is occurring as the continuation of other colonial legacies such as poverty and 
malnutrition – and these are the “preconditions … being strategically used by the 
pharmaceutical investment business to conquer and expand these markets for their 
patented drugs” 36.  The book’s emphasis is on economic dependency with the west, and 
that pharmaceutical colonialism is disguised as “charity for people in need … suffering 
from diseases”, and has “infiltrated government bodies, corporate structures and civil 
society in many countries”, and it can be “recognized by their common denominator, they 
all seek to cement and expand the monopoly of the investment business with patented 
pharmaceutical drugs on global health”37.   
 
The Rath Foundation book does not mention the practice of unethical drug trials in 
Africa, as a source of this ‘colonisation’, and instead offers a notable divergence to the 
debate and definition of pharmaceutical colonialism put forward by Chippaux.  Overall, 
Rath’s arguments cannot be taken seriously, but some of the conclusions are similar. 
Indeed, it is more likely that the anti-retrovirals and other drugs designed to combat 
HIV/AIDS are simply being tested in Africa and elsewhere, so that they can be sold to 
those who can afford them in the west, either western HIV/AIDs patients, or to 
philanthropic organizations (who may redistribute them within Africa).  In practice, there 
is no incentive for the pharmaceutical industry to colonise Africa to market its drugs (as 
Rath claims), because there is no profit to be made38.  Indeed, the pharmaceutical 
industry now relies upon philanthropic organizations such as Bill and Melinda Gates 
                                                 
35
 See Steven Friedman and Shauna Mottiar “A Rewarding Engagement? The Treatment Action Campaign 
and the Politics of HIV/AIDS”, in Politics and Society, Vol.33, no.4, December 2005, pp.511-565 
36
 Dr. Rath Health Foundation, pp.28-30. 
37
 Dr. Rath Health Foundation, p.32 
38
 It is not in the financial interests of a drug company to develop a drug that cannot be marketed in the 
west.  Only 1% of available drugs are designed to combat tropical diseases.  If the pharmaceutical industry 
is setting out to find a cure for HIV/AIDS, or other tropical diseases, they claim it is for the ‘greater global 
good’, even if only to curtail global health security threats to the west, and not any altruistic good to help 
poor people. 
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Foundation to create financial incentives through public/private partnerships to invest in 
AIDS drugs development, in order to help curtail the spread of HIV in Africa39. 
 
Therefore, in our attempts to define the concept of pharmaceutical colonialism in Africa, 
we can now ignore the components of the argument offered by the Rath Foundation, and 
instead focus our attention on more recent and realistic problems facing the continent in 
light of unethical drug trials.  When Sonia Shah published her book The Body Hunters: 
Testing New Drugs on the World’s Poorest Patients  in 2006, the concept of 
‘pharmaceutical colonialism’ and the associated unethical actions of global 
pharmaceutical corporations came together.  However, given the above discussion on the 
various definitions of ‘pharmaceutical colonialism, could it also be defined in relation to 
‘do-gooder’40 or ‘missionary’ style colonialism, interventions to save the ‘heathens’ from 
their own ‘savagery’ and ‘disease’? 
 
For example, the pharmaceutical industry does have drugs that can help prevent the 
transmission of HIV/AIDS between mother and baby, and Africa has a very large market 
for them.  The problem of course is financial and political within Africa to afford such 
modern medical wonders.  For example, when South Africa, arguably the strongest state 
on the African continent, refuses to allow its citizens access to proven western medicines 
(for whatever political or economic motivations), due to the costs of this ‘colonialism’ 
(the costs of the expensive anti-retroviral drugs), and instead they subscribe to the anti-
colonial views of the Dr. Rath Foundation, what does this conclude therefore about the 
role of global pharmaceutical companies in the (re)colonization of, or strategic  
imperialism in, Africa?  Indeed what does it say about the strength of a state to protects 
its citizens from pandemic diseases?  Bob Marsella summarises the answers when he 
posited the reason for Thabo Mbeki’s rejection of successful anti-retroviral drugs, in that 
                                                 
39
 See Bloom, 2007, p.37; Rothman and Rothman, 2006, p.87; Shah, 2006, pp.165-166; and see Nana Poku, 
“The Global AIDS Fund: Context and Opportunity”, in Nana Poku and Alan Whiteside, eds.,  Global 
Health Governance: HIV/AIDS, (Palgrave, MacMillan, New York, 2004).   
40
 Martha Nussbaum first refers to “do-gooder colonialism” in her “Introduction”, in Nussbaum M, Glover 
J., eds., Women, culture and development: a study of human capabilities, (Oxford, Clarendon Press, 1995), 
p.4; cited in Leila Toivianen, “Editorial Comment”, Nursing Ethics, 14, 6, (2007), pp. 715. 
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it was “more a question of: what are they going to do with all of those orphans and how 
are they going to support them when their parents both die?”41 
 
However, are these best-intentions interventions by global philanthropists such as the Bill 
and Melinda Gates Foundation, and other PPPs also part of this ‘colonisation project’?  
Are their actions patronizing, colonizing or simply caring?   Is this ‘do-gooder’ 
colonialism, welcomed by the colonized? Skeptical opponents to western medicine (such 
as the Dr. Rath Foundation) would reject these interventions as a form of ‘genocide’42.    
Sonia Shah has argued that although the quest for simple solutions driven by the PPPs is 
noble and could improve the lives of people in developing countries, these actions,  
do little to extract the poor from their health care-deprived environments bereft of 
clean water and electricity. On the contrary, in effect they engineer ways for people 
to survive them indefinitely43. 
A case of damned if you do and damned if you don’t! 
 
However, when the state cannot protect its citizens against encroaching disease epidemics 
or pandemics (because they are weak states), is there a role for foreign intervention from, 
for example, philanthropic organizations, even if these interventions result in unethical 
drug trials, and even if they result in a type of colonization?  The dilemma for the drug 
industry is that while African countries offer a potentially huge market for antiretroviral 
drugs to combat HIV/AIDS, they simply cannot afford to pay for them, and so they do 
not invest in the research and development necessary to help them44. Hence, this is the 
role for global philanthropists to provide this incentive to continue research and 
development into such diseases that affect more people in developing countries, and to 
promote the strategies to try and provide cheaper generic drugs to those populations. 
 
Perhaps part of the problem could arise from one of the hallmarks of the anti-
globalisation tirade, in that these philanthropists and other PPPs are not democratically 
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 Bob Marsella quoted in Shah, 2006, p.108 
42
 The Rath Foundation, pp.80-83 
43
 Shah, 2006, p.166 
44
 Caroline Thomas, “Trade Policy and the Politics of Access to Drugs”, in Nana Poku and Alan Whiteside, 
eds., Global Health Governance: HIV/AIDS, (Palgrave, MacMillan, New York, 2004). 
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elected representatives of any countries, yet their budgets are bigger (and yes, in some 
cases their hearts!). While the Gates Foundation donated over $6 billion in 1999, “the 
entire annual budget of the World Health Organisation is less than $1 billion”45.  Do we 
trust or fear these unelected players?   Is it ‘for their own good’ that we must intervene 
and assist, or should we ignore the plight of millions of Africans suffering from the 
effects of HIV and other diseases on their lives, and indeed deaths, simply because their 
‘elected’ leaders reject foreign intervention (on whatever grounds)? 
 
In getting the mixture of good intentions and perceived ‘colonialism’ (or strategic 
imperialism) right in this new millennium (nearly three decades after fears of 
pharmaceutical colonialism emerge from the third world), can the Public-Private 
Partnerships (PPPs) themselves instead be seen as “potentially radical new systems of 
global governance”46, and thus play a central role in improving global health for all, 
where states cannot?  Indeed, it would seem that the existence of PPPs reflects a 
weakness of the state to provide for its citizens, in which case the fears of pharmaceutical 
colonialism or strategic imperialism are based on the concern that these global players are 
taking advantage of the weakness in the nation-state with the aim to profit only from the 
relationship. Tony Evans argues that it has been globalization that has eroded the capacity 
of the state to provide for its own citizens and therefore, 
the state may no longer possess the capabilities to support the social determinants of 
health. Whereas people once looked to their own state ordered institutions to 
provide the infrastructures for organizing economic, social and cultural life today 
the conditions of globalization have seen the creation of a global order where 
corporate and financial interests prevail over the interests of populations47. 
Arguably, many African states have never been strong or successful enough to provide 
such order (and health systems), either during colonialism or in the post-colonial period.  
                                                 
45
 Nana Poku and Alan Whiteside, eds., Global Health Governance: HIV/AIDS, (Palgrave, MacMillan, 
New York, 2004), p.2. 
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Governance?” in Bulletin of the World Health Organisation, July 2000, cited in Poku and Whiteside, 
(2004), p. 2. 
47
 Tony Evans, “A Human Right to Health?”, in, Nana Poku and Alan Whiteside, (eds) Global Health 
Governance: HIV/AIDS, (Palgrave, MacMillan, New York, 2004), p.19. 
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Thus it is a common global order within Africa that foreign, corporate financial interests 
have prevailed. 
 
We can now juxtapose the image of the ‘great white hunter’ from colonial Africa, with 
the pharmaceutical ‘body hunters’ of today.  Pharmaceutical corporations are 
‘colonizing’ African countries and other developing regions to some extent, however 
strategically.  Poor and disease burdened people from developing countries are being 
exploited for resource extraction through the processes of globalisation and 
pharmaceutical colonialism.  Contract Research Organizations taking advantage of the 
processes of globalization have outsourced clinical trials to developing countries, and 
enlisted as ‘subjects’ the world’s poorest, most disease burdened and vulnerable 
communities.  In the various drug trials that have been conducted (such as for Tenofovir48 
and  Nitazoxanide49) participant’s bodies become colonial subjects. Rothman and 
Rothman note that “abject poverty is harsh enough without having to bear the additional 
burdens of serving as research subjects”50, but that is the harsh reality of globalisation on 
developing countries.  However, unlike the ‘Scramble for Africa’ in 1885, the 
pharmaceutical industry these days does not need to colonise any of these countries, 
because they can still get their data simply through the processes of globalization51, 
combined with a ‘strategic imperialism’, which “imposes rules upon the poor without 
their consent”52.  Chippaux points out the existence of an “unacceptable relativism”, 
which argues that you cannot “apply the rules of the rich to those who are not in a 
position to endorse them”53.  Just because they are poor, black Africans susceptible to 
disease, but without a strong state with strict health guidelines and ethical regulations, 
does not mean that they can be exploited for experimentation, and be ‘volunteered’ as 
subjects in drug trials to benefit others, and indeed drug trials that would not be approved 
of in the west, and if so, would find no volunteers there.   
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Ironically, medical research is about improving global health for all, and saving lives.  As 
Rothman and Rothman illustrate, AIDS researchers have argued that AIDS “is so 
dreadful … [they] must be given a relatively free hand in order to find useful 
treatments”54.  Are those researchers who are conducting trials of questionable ethics 
‘enthusiastic or reluctant colonisers’?55  This is the patronizing colonial project – 
ultimately it is for their own good, that some must suffer.  But this has resulted in 
“exploitation and human rights violations”56, where profit driven pharmaceutical 
corporations can take advantage of the developing world, “not to cure AIDS but to 
increase their returns”57.  After all they are businesses, not charities.   There is no time for 
altruistic participants to come forth to develop new drugs. Profits are required now.   This 
is central to the concept of ‘pharmaceutical colonialism’.   
 
If the economic conditions were different, and African governments could afford western 
standards of health care and buy the drugs necessary for the best method of treatment, for 
whatever disease or illness, would the CROs still prefer those populations to test their 
drugs?  Without needing to agree to the outrageous claims made by the Rath Foundation,  
the processes involved in global clinical trials do suggest that globalization enables 
pharmaceutical colonialism in weak states. 
 
Thus, it would seem that the relationship between the global pharmaceutical corporations 
and the potential pool of bodies available to them in the developing world is not just 
simply ‘colonial’.  If the pharmaceutical company was colonizing the country (or its 
people) then they would be able to control or manipulate local governments for the 
purpose of their exploitative resource extraction (human bio-data).  However, it is more a 
process of globalization because it can also involve the actions of the local government or 
associated health institutions, doing deals with the big pharmaceutical companies to 
invest in their ailing health infrastructure at whatever costs to the pool of poor human 
resources.  If the local government approves of the ‘foreign intervention’ (through the 
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55
 Perhaps one could ask those Pfizer researchers eventually arrested in Nigeria over the Trovan trials in 
Kano, 1996. 
56
 Shah, 2006, p.175 
57
 Rothman and Rothman, 2006, p.73 
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existence of an ethics committee), invites the pharmaceutical company to test its drugs (in 
return for something, like access to drugs, a new medical ward, or a Mercedes) then this 
suggests a combination of globalization and colonialism is at work in the activities of the 
global pharmaceutical industry.  The concept of  “globonialism” could thus be coined 
here, as a short hand term for the global activities of clinical research organizations, 
exploiting poor people in developing countries with dubious and unethical clinical drug 
trials, that intend only to benefit markets in the west. However, what is more likely is that 
Chippaux’s ‘strategic imperialism’ will continue in weak nations, while global 
corporations gain increased strength through increased profits. 
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